LATEST ALERTS
The US Drug Enforcement Agency (DEA) is calling for an increase in production of cannabis and psychedelics to supply federal research and clinical trials.
In a notice published on the US government’s daily journal the Federal Register, the DEA said the increase in production applied specifically to schedule I substances such as psilocybin, psilocin, cannabis and cannabis extracts.
...Are you already a subscriber? login here
CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
